News & Events about Pharvaris Nv.
Globe Newswire
2 months ago
ZUG, Switzerland, March 18, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced an oral presentation of positive data from its Phase 2 RAPIDe-1 ...
Globe Newswire
3 months ago
ZUG, Switzerland, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced a poster detailing positive data from its Phase 2 RAPIDe-1 study ...
Shares of Pharvaris (NASDAQ:PHVS Get Rating) have earned an average recommendation of Moderate Buy from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has ...
Ticker Report
4 months ago
Pharvaris (NASDAQ:PHVS Get Rating) had its price objective trimmed by SVB Leerink from $20.00 to $18.00 in a report released on Friday, Benzinga reports. The firm currently has an outperform rating on the stock. Separately, JMP Securities increased their target price on Pharvaris from $22.00...
Ticker Report
4 months ago
Shares of Pharvaris (NASDAQ:PHVS Get Rating) have been given an average recommendation of Moderate Buy by the six ratings firms that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued...